Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 49

References for PMC Articles for PubMed (Select 19365082)

1.

Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-transduced CD34+ cells.

Kim YJ, Kim YS, Larochelle A, Renaud G, Wolfsberg TG, Adler R, Donahue RE, Hematti P, Hong BK, Roayaei J, Akagi K, Riberdy JM, Nienhuis AW, Dunbar CE, Persons DA.

Blood. 2009 May 28;113(22):5434-43. doi: 10.1182/blood-2008-10-185199. Epub 2009 Apr 1.

2.

Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.

Pestina TI, Hargrove PW, Jay D, Gray JT, Boyd KM, Persons DA.

Mol Ther. 2009 Feb;17(2):245-52. doi: 10.1038/mt.2008.259. Epub 2008 Dec 2.

3.

Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice.

Chang AH, Stephan MT, Lisowski L, Sadelain M.

Mol Ther. 2008 Oct;16(10):1745-52. doi: 10.1038/mt.2008.161. Epub 2008 Aug 5.

4.

Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells.

Milsom MD, Jerabek-Willemsen M, Harris CE, Schambach A, Broun E, Bailey J, Jansen M, Schleimer D, Nattamai K, Wilhelm J, Watson A, Geiger H, Margison GP, Moritz T, Baum C, Thomale J, Williams DA.

Cancer Res. 2008 Aug 1;68(15):6171-80. doi: 10.1158/0008-5472.CAN-08-0320.

5.

In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia.

Miccio A, Cesari R, Lotti F, Rossi C, Sanvito F, Ponzoni M, Routledge SJ, Chow CM, Antoniou MN, Ferrari G.

Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10547-52. doi: 10.1073/pnas.0711666105. Epub 2008 Jul 23.

6.

Development of gene therapy for blood disorders.

Nienhuis AW.

Blood. 2008 May 1;111(9):4431-44. doi: 10.1182/blood-2007-11-078121. Review.

7.

Physiological promoters reduce the genotoxic risk of integrating gene vectors.

Zychlinski D, Schambach A, Modlich U, Maetzig T, Meyer J, Grassman E, Mishra A, Baum C.

Mol Ther. 2008 Apr;16(4):718-25. doi: 10.1038/mt.2008.5. Epub 2008 Mar 4.

PMID:
18334985
8.

In vivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector.

Cai S, Ernstberger A, Wang H, Bailey BJ, Hartwell JR, Sinn AL, Eckermann O, Linka Y, Goebel WS, Hanenberg H, Pollok KE.

Exp Hematol. 2008 Mar;36(3):283-92. doi: 10.1016/j.exphem.2007.11.009.

9.

Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation.

Zhang CC, Kaba M, Iizuka S, Huynh H, Lodish HF.

Blood. 2008 Apr 1;111(7):3415-23. doi: 10.1182/blood-2007-11-122119. Epub 2008 Jan 17.

10.

Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells.

Hargrove PW, Kepes S, Hanawa H, Obenauer JC, Pei D, Cheng C, Gray JT, Neale G, Persons DA.

Mol Ther. 2008 Mar;16(3):525-33. doi: 10.1038/sj.mt.6300394. Epub 2008 Jan 15.

PMID:
18195719
11.

An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.

Ryu BY, Evans-Galea MV, Gray JT, Bodine DM, Persons DA, Nienhuis AW.

Blood. 2008 Feb 15;111(4):1866-75. Epub 2007 Nov 8.

12.

Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression.

Ball CR, Pilz IH, Schmidt M, Fessler S, Williams DA, von Kalle C, Glimm H.

Blood. 2007 Sep 15;110(6):1779-87. Epub 2007 May 11.

13.

Murine retroviral but not human cellular promoters induce in vivo erythroid-specific deregulation that can be partially prevented by insulators.

Robert-Richard E, Richard E, Malik P, Ged C, de Verneuil H, Moreau-Gaudry F.

Mol Ther. 2007 Jan;15(1):173-82.

PMID:
17164789
14.

Partial correction of murine beta-thalassemia with a gammaretrovirus vector for human gamma-globin.

Nishino T, Tubb J, Emery DW.

Blood Cells Mol Dis. 2006 Jul-Aug;37(1):1-7. Epub 2006 Jun 30.

PMID:
16814578
15.

Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells.

Zhang CC, Kaba M, Ge G, Xie K, Tong W, Hug C, Lodish HF.

Nat Med. 2006 Feb;12(2):240-5. Epub 2006 Jan 22.

16.

Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.

Schambach A, Bohne J, Chandra S, Will E, Margison GP, Williams DA, Baum C.

Mol Ther. 2006 Feb;13(2):391-400. Epub 2005 Oct 12.

PMID:
16226060
17.

Stem cell transplantation and gene therapy for hemoglobinopathies.

Gaziev J, Lucarelli G.

Curr Hematol Rep. 2005 Mar;4(2):126-31. Review.

PMID:
15720961
18.

Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia.

Hanawa H, Hargrove PW, Kepes S, Srivastava DK, Nienhuis AW, Persons DA.

Blood. 2004 Oct 15;104(8):2281-90. Epub 2004 Jun 15.

19.
20.

Pois(s)on--it's a question of dose...

Fehse B, Kustikova OS, Bubenheim M, Baum C.

Gene Ther. 2004 Jun;11(11):879-81. Review. No abstract available.

PMID:
15057265
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk